ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "b8cb6d09-58e1-4cfe-9811-b74232c40d48"}, "_deposit": {"id": "30411", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "30411"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:00030411", "sets": ["2518"]}, "item_9_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2020-08", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3", "bibliographicPageEnd": "414", "bibliographicPageStart": "407", "bibliographicVolumeNumber": "82", "bibliographic_titles": [{"bibliographic_title": "Nagoya Journal of Medical Science"}]}]}, "item_9_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Prolonged treatment with linezolid (LZD) is known to cause thrombocytopenia. However, some patients do not develop thrombocytopenia despite long-term administration of LZD. To determine the risk factors for LZD-associated thrombocytopenia in patients undergoing long-term LZD therapy, we conducted a retrospective cohort study among 212 patients receiving LZD treatment between December 2011 and June 2014 at a tertiary referral university hospital in Nagoya, Japan. Of the 217 patients who received LZD, 37 were treated with LZD for more than 14 days and were enrolled in the study. We compared data on demographic characteristics, underlying disease, microbiology, concomitant drugs, and laboratory tests between the thrombocytopenia group and the non-thrombocytopenia group. Thrombocytopenia was defined as having a platelet count \u003c 100 × 103/μL or a ≥ 50% reduction in platelet count compared to baseline. Among the 37 patients who received LZD for more than 14 days, 17 (45.9%) developed thrombocytopenia. Multivariate logistic regression revealed that both the number of concomitant drugs with thrombocytopenic adverse effects (DTADE) (OR = 1.690; 95% CI = 1.037–2.754; P = 0.035) and a small decrease in the level of C-reactive protein (CRP) 14 days post-administration (OR = 0.965; 95% CI = 0.939–0.993; P = 0.013) were associated with thrombocytopenia during long-term LZD therapy. Therefore, the number of concomitant DTADE and a small decrease in CRP on the 14th day of treatment were key factors for the appearance of LZD-associated thrombocytopenia in patients with long-term LZD therapy. Our findings may be useful for preventing thrombocytopenia in patients treated with LZD for longer than 14 days.", "subitem_description_type": "Abstract"}]}, "item_9_identifier_registration": {"attribute_name": "ID登録", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.18999/nagjms.82.3.407", "subitem_identifier_reg_type": "JaLC"}]}, "item_9_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Nagoya University Graduate School of Medicine, School of Medicine"}]}, "item_9_relation_43": {"attribute_name": "異版である", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/823.html ", "subitem_relation_type_select": "URI"}}]}, "item_9_select_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_9_source_id_61": {"attribute_name": "ISSN(Online)", "attribute_value_mlt": [{"subitem_source_identifier": "2186-3326", "subitem_source_identifier_type": "ISSN"}]}, "item_9_source_id_7": {"attribute_name": "ISSN(print)", "attribute_value_mlt": [{"subitem_source_identifier": "0027-7622", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Sato, Yoshitaka"}], "nameIdentifiers": [{"nameIdentifier": "100997", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Iguchi, Mitsutaka"}], "nameIdentifiers": [{"nameIdentifier": "100998", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kato, Yoshiaki"}], "nameIdentifiers": [{"nameIdentifier": "100999", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Morioka, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "101000", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hirabayashi, Aki"}], "nameIdentifiers": [{"nameIdentifier": "101001", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tetsuka, Nobuyuki"}], "nameIdentifiers": [{"nameIdentifier": "101002", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tomita, Yuka"}], "nameIdentifiers": [{"nameIdentifier": "101003", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kato, Daizo"}], "nameIdentifiers": [{"nameIdentifier": "101004", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamada, Kiyofumi"}], "nameIdentifiers": [{"nameIdentifier": "101005", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kimura, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "101006", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yagi, Tetsuya"}], "nameIdentifiers": [{"nameIdentifier": "101007", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-09-04"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "03_Sato.pdf", "filesize": [{"value": "195.7 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 195700.0, "url": {"label": "03_Sato.pdf", "url": "https://nagoya.repo.nii.ac.jp/record/30411/files/03_Sato.pdf"}, "version_id": "b7f77974-0b02-4d9e-9af2-e396d2e4c873"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "linezolid", "subitem_subject_scheme": "Other"}, {"subitem_subject": "thrombocytopenia", "subitem_subject_scheme": "Other"}, {"subitem_subject": "bacterial infection", "subitem_subject_scheme": "Other"}, {"subitem_subject": "MRSA", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Number of concomitant drugs with thrombocytopenic adverse effects and the extent inflammatory response resolution are risk factors for thrombocytopenia in patients treated with linezolid for more than 14 days", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Number of concomitant drugs with thrombocytopenic adverse effects and the extent inflammatory response resolution are risk factors for thrombocytopenia in patients treated with linezolid for more than 14 days"}]}, "item_type_id": "9", "owner": "1", "path": ["2518"], "permalink_uri": "https://doi.org/10.18999/nagjms.82.3.407", "pubdate": {"attribute_name": "公開日", "attribute_value": "2020-09-04"}, "publish_date": "2020-09-04", "publish_status": "0", "recid": "30411", "relation": {}, "relation_version_is_last": true, "title": ["Number of concomitant drugs with thrombocytopenic adverse effects and the extent inflammatory response resolution are risk factors for thrombocytopenia in patients treated with linezolid for more than 14 days"], "weko_shared_id": 3}
  1. C100 医学部/医学系研究科
  2. C100b 紀要
  3. Nagoya journal of medical science
  4. 82(3)

Number of concomitant drugs with thrombocytopenic adverse effects and the extent inflammatory response resolution are risk factors for thrombocytopenia in patients treated with linezolid for more than 14 days

https://doi.org/10.18999/nagjms.82.3.407
https://doi.org/10.18999/nagjms.82.3.407
ac17adc5-f4e3-4e6c-8fda-3c988a2408d1
名前 / ファイル ライセンス アクション
03_Sato.pdf 03_Sato.pdf (195.7 kB)
Item type 紀要論文 / Departmental Bulletin Paper(1)
公開日 2020-09-04
タイトル
タイトル Number of concomitant drugs with thrombocytopenic adverse effects and the extent inflammatory response resolution are risk factors for thrombocytopenia in patients treated with linezolid for more than 14 days
著者 Sato, Yoshitaka

× Sato, Yoshitaka

WEKO 100997

Sato, Yoshitaka

Search repository
Iguchi, Mitsutaka

× Iguchi, Mitsutaka

WEKO 100998

Iguchi, Mitsutaka

Search repository
Kato, Yoshiaki

× Kato, Yoshiaki

WEKO 100999

Kato, Yoshiaki

Search repository
Morioka, Hiroshi

× Morioka, Hiroshi

WEKO 101000

Morioka, Hiroshi

Search repository
Hirabayashi, Aki

× Hirabayashi, Aki

WEKO 101001

Hirabayashi, Aki

Search repository
Tetsuka, Nobuyuki

× Tetsuka, Nobuyuki

WEKO 101002

Tetsuka, Nobuyuki

Search repository
Tomita, Yuka

× Tomita, Yuka

WEKO 101003

Tomita, Yuka

Search repository
Kato, Daizo

× Kato, Daizo

WEKO 101004

Kato, Daizo

Search repository
Yamada, Kiyofumi

× Yamada, Kiyofumi

WEKO 101005

Yamada, Kiyofumi

Search repository
Kimura, Hiroshi

× Kimura, Hiroshi

WEKO 101006

Kimura, Hiroshi

Search repository
Yagi, Tetsuya

× Yagi, Tetsuya

WEKO 101007

Yagi, Tetsuya

Search repository
キーワード
主題Scheme Other
主題 linezolid
キーワード
主題Scheme Other
主題 thrombocytopenia
キーワード
主題Scheme Other
主題 bacterial infection
キーワード
主題Scheme Other
主題 MRSA
抄録
内容記述 Prolonged treatment with linezolid (LZD) is known to cause thrombocytopenia. However, some patients do not develop thrombocytopenia despite long-term administration of LZD. To determine the risk factors for LZD-associated thrombocytopenia in patients undergoing long-term LZD therapy, we conducted a retrospective cohort study among 212 patients receiving LZD treatment between December 2011 and June 2014 at a tertiary referral university hospital in Nagoya, Japan. Of the 217 patients who received LZD, 37 were treated with LZD for more than 14 days and were enrolled in the study. We compared data on demographic characteristics, underlying disease, microbiology, concomitant drugs, and laboratory tests between the thrombocytopenia group and the non-thrombocytopenia group. Thrombocytopenia was defined as having a platelet count < 100 × 103/μL or a ≥ 50% reduction in platelet count compared to baseline. Among the 37 patients who received LZD for more than 14 days, 17 (45.9%) developed thrombocytopenia. Multivariate logistic regression revealed that both the number of concomitant drugs with thrombocytopenic adverse effects (DTADE) (OR = 1.690; 95% CI = 1.037–2.754; P = 0.035) and a small decrease in the level of C-reactive protein (CRP) 14 days post-administration (OR = 0.965; 95% CI = 0.939–0.993; P = 0.013) were associated with thrombocytopenia during long-term LZD therapy. Therefore, the number of concomitant DTADE and a small decrease in CRP on the 14th day of treatment were key factors for the appearance of LZD-associated thrombocytopenia in patients with long-term LZD therapy. Our findings may be useful for preventing thrombocytopenia in patients treated with LZD for longer than 14 days.
内容記述タイプ Abstract
出版者
出版者 Nagoya University Graduate School of Medicine, School of Medicine
言語
言語 eng
資源タイプ
資源 http://purl.org/coar/resource_type/c_6501
タイプ departmental bulletin paper
ID登録
ID登録 10.18999/nagjms.82.3.407
ID登録タイプ JaLC
関連情報
関連タイプ isVersionOf
識別子タイプ URI
関連識別子 http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/823.html
ISSN(print)
収録物識別子タイプ ISSN
収録物識別子 0027-7622
ISSN(Online)
収録物識別子タイプ ISSN
収録物識別子 2186-3326
書誌情報 Nagoya Journal of Medical Science

巻 82, 号 3, p. 407-414, 発行日 2020-08
著者版フラグ
値 publisher
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 08:48:28.231777
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3